Login
Navigate Fool.com
Will DNDN beat
the market?

Dendreon Corp

NASDAQ: DNDN

Community Rating: 2 Stars: Unattractive

3.99 -0.09 (-2.21%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.10
Previous Close $4.08
Daily Range $3.98 - $4.11
52-Week Range $3.69 - $7.94
Market Cap $628.8M
P/E Ratio -1.68
Dividend (Yield) $0.00 (0.0%)
Volume 2,335,977
Average Daily Volume 4,581,523
Current FY EPS -$1.60

How do you think DNDN
will perform against the market?

Top DNDN Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted August 5, 2011

Wow. I haven't followed Dendreon closely since I predicted incorrectly that their repeat phase III trial of Provenge would fail. I maintained some skepticism about the commercial potential of Provenge … More

0 Replies Reply Report this Post
 

DarthMaul09 (< 20)
Submitted November 5, 2011

Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acce … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

One Person's Trash Is Another Person's Treasure Portfolio

A yearlong exercise intent on proving that value and contrarian investing can be incredibly successful.

Beware the Bullishness on Bristol-Myers

3 Reasons You Shouldn't Buy Stocks in Biotech

Wondering if you should buy stocks in biotech? Here are 3 reasons why you might want to take a pass.

Why Progenics Is Poised to Plunge

Market-lagging returns could be written in this 2-star stock.

A Promising Platform for Cancer Immunotherapy

A Promising Platform for Cancer Immunotherapy

Pre-Market Most Active for May 31, 2013 : BAC, NOK, SPIL, BBRY, AL, RDS/A, ING, DNDN, SIRI, NBG, OV

Pre-Market Most Active for May 31, 2013 : BAC, NOK, SPIL, BBRY, AL, RDS/A, ING, DNDN, SIRI, NBG, OVTI, FB

Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2013 ASCO Annual Meeting

This Cancer Drug Developer Could Really Use a Partner

This company's lead drug will beef up your immune system to fight cancer, but it could sorely use a marketing partner to help drum up sales.

One Person's Trash Is Another Person's Treasure Portfolio

A year-long exercise intent on proving that value and contrarian investing can be incredibly successful.

See More DNDN News...

Sector

Healthcare

Industry

Drugs

Dendreon Corp (DNDN) Description

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website: http://www.dendreon.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks